Company profile
Rezolute, Inc.
NASDAQ:RZLTBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Ersodetug | phase3 | — | 1 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06881992 | phase3 | recruiting | 2025-04-16 | 2027-09-01 | Rezolute | A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism |
| NCT04538989 | phase2 | completed | 2020-02-24 | 2022-04-05 | Rezolute | An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism |
| NCT06208215 | phase3 | active_not_recruiting | 2024-01-11 | 2025-11-14 | Rezolute | RZ358 Treatment for Congenital Hyperinsulinism |
| NCT05712720 | phase2 | completed | 2023-02-06 | 2024-04-11 | Rezolute | Study to Evaluate the Efficacy and Safety of RZ402 in Diabetic Macular Edema (DME) |
FDA applications (0)
No records yet.